O	0	7	Effects
O	8	10	of
O	11	12	a
B-intervention	13	18	green
I-intervention	19	22	tea
I-intervention	23	30	extract
I-intervention	30	31	,
I-intervention	32	42	Polyphenon
I-intervention	43	44	E
O	44	45	,
O	46	48	on
O	49	57	systemic
O	58	68	biomarkers
O	69	71	of
O	72	78	growth
O	79	85	factor
O	86	96	signalling
O	97	99	in
O	100	105	women
O	106	110	with
O	111	118	hormone
O	119	127	receptor
O	127	128	-
O	128	136	negative
O	137	143	breast
O	144	150	cancer
O	150	151	.

O	152	165	Observational
O	166	169	and
O	170	182	experimental
O	183	187	data
O	188	195	support
O	196	197	a
O	198	207	potential
O	208	214	breast
O	215	221	cancer
O	222	237	chemopreventive
O	238	244	effect
O	245	247	of
O	248	253	green
O	254	257	tea
O	257	258	.

O	259	261	We
O	262	271	conducted
O	272	274	an
O	275	284	ancillary
O	285	290	study
O	291	296	using
O	297	305	archived
O	306	311	blood
O	311	312	/
O	312	317	urine
O	318	322	from
O	323	324	a
O	325	330	phase
O	331	333	IB
O	334	344	randomised
O	344	345	,
O	346	353	placebo
O	353	354	-
O	354	364	controlled
O	365	369	dose
O	370	380	escalation
O	381	386	trial
O	387	389	of
O	390	392	an
O	393	397	oral
O	398	403	green
O	404	407	tea
O	408	415	extract
O	415	416	,
O	417	427	Polyphenon
O	428	429	E
O	430	431	(
O	431	435	Poly
O	436	437	E
O	437	438	)
O	438	439	,
O	440	442	in
O	443	449	breast
O	450	456	cancer
O	457	465	patients
O	465	466	.

O	467	472	Using
O	473	475	an
O	476	484	adaptive
O	485	490	trial
O	491	497	design
O	497	498	,
B-eligibility	499	504	women
I-eligibility	505	509	with
I-eligibility	510	515	stage
I-eligibility	516	517	I
I-eligibility	517	518	-
I-eligibility	518	521	III
I-eligibility	522	528	breast
I-eligibility	529	535	cancer
I-eligibility	536	539	who
I-eligibility	540	549	completed
I-eligibility	550	558	adjuvant
I-eligibility	559	568	treatment
O	569	573	were
O	574	584	randomised
O	585	587	to
O	588	592	Poly
O	593	594	E
O	595	598	400
O	599	601	mg
O	602	603	(
O	603	604	n
O	605	606	=
B-intervention-participants	607	609	16
O	609	610	)
O	610	611	,
O	612	615	600
O	616	618	mg
O	619	620	(
O	620	621	n
O	622	623	=
B-intervention-participants	624	626	11
O	626	627	)
O	628	631	and
O	632	635	800
O	636	638	mg
O	639	640	(
O	640	641	n
O	642	643	=
B-intervention-participants	644	645	3
O	645	646	)
O	647	652	twice
O	653	658	daily
O	659	661	or
O	662	670	matching
B-control	671	678	placebo
O	679	680	(
O	680	681	n
O	682	683	=
B-control-participants	684	686	10
O	686	687	)
O	688	691	for
O	692	693	6
O	694	700	months
O	700	701	.

O	702	707	Blood
O	708	711	and
O	712	717	urine
O	718	728	collection
O	729	737	occurred
O	738	740	at
O	741	749	baseline
O	749	750	,
O	751	754	and
O	755	757	at
O	758	759	2
O	759	760	,
O	761	762	4
O	763	766	and
O	767	768	6
O	769	775	months
O	775	776	.

O	777	787	Biological
O	788	797	endpoints
O	798	806	included
B-outcome-Measure	807	813	growth
I-outcome-Measure	814	820	factor
I-outcome-Measure	821	822	[
I-outcome-Measure	822	827	serum
I-outcome-Measure	828	838	hepatocyte
I-outcome-Measure	839	845	growth
I-outcome-Measure	846	852	factor
I-outcome-Measure	853	854	(
I-outcome-Measure	854	857	HGF
I-outcome-Measure	857	858	)
I-outcome-Measure	858	859	,
I-outcome-Measure	860	868	vascular
I-outcome-Measure	869	880	endothelial
I-outcome-Measure	881	887	growth
I-outcome-Measure	888	894	factor
I-outcome-Measure	895	896	(
I-outcome-Measure	896	900	VEGF
I-outcome-Measure	900	901	)
I-outcome-Measure	901	902	]
I-outcome-Measure	902	903	,
I-outcome-Measure	904	909	lipid
I-outcome-Measure	910	911	(
I-outcome-Measure	911	916	serum
I-outcome-Measure	917	928	cholesterol
I-outcome-Measure	928	929	,
I-outcome-Measure	930	943	triglycerides
I-outcome-Measure	943	944	)
O	944	945	,
B-outcome-Measure	946	955	oxidative
I-outcome-Measure	956	962	damage
O	963	966	and
B-outcome-Measure	967	979	inflammatory
I-outcome-Measure	980	990	biomarkers
O	990	991	.

O	992	996	From
O	997	1001	July
O	1002	1006	2007
O	1006	1007	-
O	1007	1013	August
O	1014	1018	2009
O	1018	1019	,
B-total-participants	1020	1022	40
O	1023	1028	women
O	1029	1033	were
O	1034	1042	enrolled
O	1043	1046	and
B-total-participants	1047	1049	34
O	1050	1051	(
B-intervention-participants	1051	1053	26
O	1054	1058	Poly
O	1059	1060	E
O	1060	1061	,
B-control-participants	1062	1067	eight
O	1068	1075	placebo
O	1075	1076	)
O	1077	1081	were
O	1082	1091	evaluable
O	1092	1095	for
O	1096	1105	biomarker
O	1106	1115	endpoints
O	1115	1116	.

O	1117	1119	At
O	1120	1121	2
O	1122	1128	months
O	1128	1129	,
O	1130	1133	the
O	1134	1138	Poly
O	1139	1140	E
O	1141	1146	group
O	1147	1148	(
O	1148	1151	all
O	1152	1156	dose
O	1157	1163	levels
O	1164	1172	combined
O	1172	1173	)
O	1174	1182	compared
O	1183	1185	to
O	1186	1193	placebo
O	1194	1197	had
O	1198	1199	a
O	1200	1211	significant
O	1212	1220	decrease
O	1221	1223	in
B-outcome	1224	1228	mean
I-outcome	1229	1234	serum
I-outcome	1235	1238	HGF
I-outcome	1239	1245	levels
O	1246	1247	(
O	1247	1248	-
O	1248	1250	12
O	1250	1251	.
O	1251	1252	7
O	1252	1253	%
O	1254	1260	versus
O	1261	1262	+
O	1262	1263	6
O	1263	1264	.
O	1264	1265	3
O	1265	1266	%
O	1266	1267	,
O	1268	1269	P
O	1270	1271	=
O	1272	1273	0
O	1273	1274	.
O	1274	1276	04
O	1276	1277	)
O	1277	1278	.

O	1279	1283	This
O	1284	1289	trend
O	1290	1299	persisted
O	1300	1302	at
O	1303	1304	4
O	1305	1308	and
O	1309	1310	6
O	1311	1317	months
O	1318	1321	but
O	1322	1325	was
O	1326	1328	no
O	1329	1335	longer
O	1336	1349	statistically
O	1350	1361	significant
O	1361	1362	.

O	1363	1366	For
O	1367	1370	the
O	1371	1375	Poly
O	1376	1377	E
O	1378	1383	group
O	1383	1384	,
B-outcome	1385	1390	serum
I-outcome	1391	1395	VEGF
O	1396	1405	decreased
O	1406	1408	by
O	1409	1411	11
O	1411	1412	.
O	1412	1413	5
O	1413	1414	%
O	1415	1417	at
O	1418	1419	2
O	1420	1426	months
O	1427	1428	(
O	1428	1429	P
O	1430	1431	=
O	1432	1433	0
O	1433	1434	.
O	1434	1436	02
O	1436	1437	)
O	1438	1441	and
O	1442	1444	13
O	1444	1445	.
O	1445	1446	9
O	1446	1447	%
O	1448	1450	at
O	1451	1452	4
O	1453	1459	months
O	1460	1461	(
O	1461	1462	P
O	1463	1464	=
O	1465	1466	0
O	1466	1467	.
O	1467	1469	05
O	1469	1470	)
O	1471	1474	but
O	1475	1478	did
O	1479	1482	not
O	1483	1489	differ
O	1490	1498	compared
O	1499	1501	to
O	1502	1509	placebo
O	1509	1510	.

O	1511	1513	At
O	1514	1515	2
O	1516	1522	months
O	1522	1523	,
O	1524	1529	there
O	1530	1533	was
O	1534	1535	a
O	1536	1541	trend
O	1542	1548	toward
O	1549	1550	a
O	1551	1559	decrease
O	1560	1562	in
B-outcome	1563	1568	serum
I-outcome	1569	1580	cholesterol
O	1581	1585	with
O	1586	1590	Poly
O	1591	1592	E
O	1593	1594	(
O	1594	1595	P
O	1596	1597	=
O	1598	1599	0
O	1599	1600	.
O	1600	1602	08
O	1602	1603	)
O	1603	1604	.

O	1605	1607	No
O	1608	1619	significant
O	1620	1631	differences
O	1632	1636	were
O	1637	1645	observed
O	1646	1649	for
O	1650	1655	other
O	1656	1666	biomarkers
O	1666	1667	.

O	1668	1671	Our
O	1672	1680	findings
O	1681	1688	suggest
O	1689	1698	potential
O	1699	1710	mechanistic
O	1711	1718	actions
O	1719	1721	of
O	1722	1725	tea
O	1726	1737	polyphenols
O	1738	1740	in
O	1741	1747	growth
O	1748	1754	factor
O	1755	1765	signalling
O	1765	1766	,
O	1767	1779	angiogenesis
O	1780	1783	and
O	1784	1789	lipid
O	1790	1800	metabolism
O	1800	1801	.
